Search the Newsreel

PMN|ProMIS Neurosciences Inc|Price:11.655|Chg%:-0.545

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases like Alzheimer's, ALS, and MSA. The company utilizes a proprietary computational platform to identify disease-specific epitopes and has product candidates such as PMN310, PMN267, and PMN442 in development. …

PMN Initiated Coverage by Chardan Capital -- Rating Set to Buy

Chardan Capital has initiated coverage on ProMIS Neurosciences (PMN) with a Buy rating and a price target of $20.00, suggesting a significant upside from its current trading price of $12.345. Despite a strong financial strength rating of 9/10, PMN holds a low GF Score™ …

ProMIS Neurosciences Inc (PMN) Balance Sheet

This article provides the balance sheet for ProMIS Neurosciences Inc (PMN), detailing quarterly and annual financial figures essential for evaluating the company's financial health. It includes data on assets, liabilities, and shareholders' equity over several fiscal years and quarters. The report offers insights into …

ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of ProMIS Neurosciences Inc (PMN) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also presents institutional shareholding data across various reporting periods and highlights recent shareholder activity including changes in holdings …

ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ProMIS Neurosciences Inc (PMN), highlighting its current price momentum score as 5.41 and ranking 79th in the Biotechnology & Medical Research industry. It identifies the stock trading within a resistance level of 15.80 and a support level …

ProMIS Neurosciences Inc. Revenue Breakdown – NASDAQ:PMN

The article provides a financial overview of ProMIS Neurosciences Inc. (NASDAQ: PMN), focusing on accessible segments and regional performance data. It highlights the company's financial information, including statements, statistics, dividends, and earnings, indicating that detailed revenue breakdowns are presented by source and country. The …

Promis Neurosciences (NASDAQ:PMN) Upgraded to "Sell" at Wall Street Zen

Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)

Guggenheim reiterated its "Buy" rating for ProMIS Neurosciences (PMN) with a $35.00 price target, following a previous "Buy" rating from Roth MKM. Despite a quarterly GAAP net loss of $8.24 million, corporate insider sentiment is positive, with increased insider buying, including a recent purchase …

H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18

H.C. Wainwright has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and maintained a target price of $18. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.